PSP001 - A First-in-disease human PEGIFN-λ Chimera
| Prosit Sole innitiated a First-in-humans study of the safety, tolerability, and pharmacokinetics of PSP001, a new type of immunomodulator form family Interfon Lambda |
| Date:2024-07-04 17:32:35 | Visits： |
| First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity. |
| Prev:Feb. 03, 2021, FDA approved IND filing and Sigle Ascending Dose trial may Proceed Next: |
